0000000000322237

AUTHOR

Fabio Pace

showing 7 related works from this author

The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease

2009

Recently, a Global definition and a classification of gastroesophageal reflux disease (GERD) were developed by Montreal Consensus Group, composed of international expert gastroenterologists. Guidelines and consensus documents are, however, infrequently accepted and adopted at a local level. The aim of this study was to measure the acceptance of Montreal Global definition of GERD consensus document by specialists in a single country (Italy) and to measure the linguistic, scientific, and practical differences between the international consensus document and the Italian version.A 2-day meeting was held in June 2007 in Rome, Italy, attended by 147 Italian physicians who were experts in gastroen…

Chest Painmedicine.medical_specialtyValidation studyEsophageal NeoplasmseducationMEDLINEDiseaseAdenocarcinomaGastroenterologyBarrett EsophagusTerminology as TopicInternal medicineHumansMedicineLanguageEvidence-Based MedicineHepatologybusiness.industryGastroenterologyRefluxSyndromeEvidence-based medicinemedicine.diseasedigestive system diseasesItalyEsophageal stenosisFamily medicinePractice Guidelines as TopicEsophageal StenosisGastroesophageal RefluxGERDbusinessPremalignant lesionEuropean Journal of Gastroenterology & Hepatology
researchProduct

Cyclic antibiotic therapy for diverticular disease: a critical reappraisal.

2010

Different symptoms have been attributed to uncomplicated diverticular disease (DD). Poor absorbable antibiotics are largely used for uncomplicated DD, mainly for symptom treatment and prevention of diverticulitis onset. Controlled trials on cyclic administration of rifaximin in DD patients were evaluated. Four controlled, including 1 double-blind and 3 open-label, randomized studies were available. Following a long-term cyclic therapy, a significant difference emerged in the global symptoms score (range: 0-18) between rifaximin plus fibers (from 6-6.5 to 1-2) and fibers alone (from 6.7 to 2-3.8), although the actual clinically relevance of such a very small difference remains to be ascertai…

Dietary FiberSettore MED/12 - GastroenterologiaEvidence-Based MedicinePatient SelectionRifamycinsDrug Administration ScheduleRifaximinAnti-Bacterial AgentsDiverticulumSettore MED/18 - Chirurgia GeneraleTreatment Outcomediverticular disease; diverticulitis; haemorrhage; rifaximin; symptoms; therapyHumansDiverticular diseasetherapysymptoms rifaximin diverticulitisDiverticulitis
researchProduct

Endoscopic treatment of gastroesophageal reflux disease.

2005

Gastroesophageal reflux disease is a common chronic disorder which has a severe effect on the patient's quality of life. In view of the high cost of medical therapy and the limitations of surgery, a variety of endoscopic techniques have been developed for the treatment of this condition, and these have shown apparently encouraging results, at least in the short term. However, promising results have been obtained in only around two-thirds of patients over a short-term follow-up period of about 6 months. Moreover, several inconsistencies have emerged between the efficacy of this form of treatment in improving symptoms and quality of life and a lack of improvement of objective parameters, such…

medicine.medical_specialtyDiseaseEndoscopy GastrointestinalREFLUX DISEASE TREATMENTQuality of life (healthcare)medicineHumansPolymethyl MethacrylateIntensive care medicinemedicine.diagnostic_testEsophageal diseasebusiness.industrySuture TechniquesGastroenterologyRefluxmedicine.diseaseChronic disordersMicrospheresEndoscopySurgeryClinical trialCatheter AblationGastroesophageal RefluxPolyvinylsbusinessEndoscopic treatmentEndoscopy
researchProduct

White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths

2014

In 2011 the three major Italian gastroenterological scientific societies (AIGO, the Italian Society of Hospital Gastroenterologists and Endoscopists; SIED, the Italian Society of Endoscopy; SIGE, the Italian Society of Gastroenterology) prepared their official document aimed at analysing medical care for digestive diseases in Italy, on the basis of national and regional data (Health Ministry and Lombardia, Veneto, Emilia-Romagna databases) and to make proposals for planning of care. Digestive diseases were the first or second cause of hospitalizations in Italy in 1999–2009, with more than 1,500,000 admissions/year; however only 5–9% of these admissions was in specialized Gastroenterology un…

MaleGastrointestinal DiseasesTreatment outcomeDiseasesMedical careGastroenterologyCancer; Digestive diseases; Emergency; Gastroenterology; Gastrointestinal bleeding; Hospital discharge record; Hospital stay; Mortality; Adolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Emergencies; Female; Gastroenterology; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Health Planning; Health Services; Health Services Needs and Demand; Hospital Mortality; Hospital Units; Humans; Incidence; Infant; Infant Newborn; Italy; Length of Stay; Male; Middle Aged; Prevalence; Societies Medical; Treatment Outcome; Young AdultHealth servicesWhite paperDigestive diseaseitaly80 and overPrevalenceMedicineCancer; Digestive diseases; Emergency; Gastroenterology; Gastrointestinal bleeding; Hospital discharge record; Hospital stay; Mortality; Adolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Emergencies; Female; Gastroenterology; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Health Planning; Health Services; Health Services Needs and Demand; Hospital Mortality; Hospital Units; Humans; Incidence; Infant; Infant Newborn; Italy; Length of Stay; Male; Middle Aged; Prevalence; Societies Medical; Treatment Outcome; Young Adult; Hepatology; GastroenterologyHospital MortalityChildSocieties MedicalCancerAged 80 and overSettore MED/12 - GastroenterologiaHospital stayIncidenceIncidence (epidemiology)GastroenterologyHealth ServicesMiddle AgedDigestive diseases Emergency Gastroenterology Gastrointestinal bleeding Hospital discharge record Hospital stay MortalityTreatment OutcomeChild PreschoolFemaleChristian ministryGastrointestinal HemorrhageHospital UnitsHospital discharge recordAdultgastroenterology; Diseases; italymedicine.medical_specialtyAdolescentYoung AdultCase mix indexMedicalInternal medicineHumansCancer Digestive diseases Emergency Gastroenterology Gastrointestinal bleeding Hospital discharge record Hospital stay MortalityMortalityPreschoolGastrointestinal bleedingAgedHealth Services Needs and DemandHepatologybusiness.industryInfant NewbornInfantLength of StayHepatologyNewbornHealth PlanningEmergencyDigestive diseasesEmergenciesSocietiesbusinessDigestive and Liver Disease
researchProduct

Microbiota Gut–Brain Axis in Ischemic Stroke: A Narrative Review with a Focus about the Relationship with Inflammatory Bowel Disease

2021

The gut microbiota is emerging as an important player in neurodevelopment and aging as well as in brain diseases including stroke, Alzheimer’s disease, and Parkinson’s disease. The complex interplay between gut microbiota and the brain, and vice versa, has recently become not only the focus of neuroscience, but also the starting point for research regarding many diseases such as inflammatory bowel diseases (IBD). The bi-directional interaction between gut microbiota and the brain is not completely understood. The aim of this review is to sum up the evidencesconcerningthe role of the gut–brain microbiota axis in ischemic stroke and to highlight the more recent evidences about the potential r…

0301 basic medicinebrainScienceGut–brain axisReviewDiseaseGut floraBioinformaticsInflammatory bowel diseasedigestive systemGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineinflammatory bowel diseasemicrobiotaMedicineStrokeEcology Evolution Behavior and Systematicsbiologybusiness.industrystroke.digestive oral and skin physiologyQPaleontologyInflammatory Bowel Diseasesbiology.organism_classificationmedicine.diseasestrokestomatognathic diseases030104 developmental biologySpace and Planetary ScienceIschemic strokegutNarrative reviewbusiness030217 neurology & neurosurgeryLife
researchProduct

Is Helicobacter pylori status relevant in the management of GORD?

2000

Summary There is growing interest in the relationship between H. pylori infection and gastro-oesophageal reflux disease (GORD). However, this relationship is complex, as yet not fully elucidated, and probably based on a multiplicity of factors. The prevalence of H. pylori infection in patients with GORD is similar, more often lower than in matched controls. There is a negative correlation between H. pylori infection and the severity of GORD. There are many hypothetical mechanisms by which H. pylori infection may protect from the development of GORD. Conversely, there are many possible mechanisms by which H. pylori infection could theoretically foster the GORD. Patients after H. pylori eradi…

medicine.medical_specialtyAtrophic gastritismedicine.drug_classProton-pump inhibitordigestive systemGastroenterologyInternal medicinemedicinePharmacology (medical)HelicobacterHepatologybiologybusiness.industryStomachdigestive oral and skin physiologyGastroenterologyIntestinal metaplasiaHelicobacter pylorimedicine.diseasebiology.organism_classificationdigestive system diseasesmedicine.anatomical_structureDysplasiaGastritismedicine.symptombusinessAlimentary Pharmacology & Therapeutics
researchProduct

Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.

2007

Proton pump inhibitors (PPIs) are antisecretory agents that are widely used in the short- and long-term management of gastroesophageal reflux disease (GERD) to relieve symptoms, heal esophagitis, and prevent complications, such as strictures and Barrett’s esophagus. The total healthcare costs of GERD are high, especially for maintenance treatment. Therefore, the choice of cost-effective therapeutic options is an ineluctable challenge for public health authorities, third-party payers, and patients. In some European Union countries, a recent trend of public health authorities is to promote the choice of less expensive PPIs, regardless of their antisecretory potency – this in spite of the evid…

medicine.medical_specialtybusiness.industryGastroenterologyRefluxAntisecretory agentsEsomeprazoleProton Pump InhibitorsDiseaseProton pump inhibitorGastroesophageal reflux diseasemedicine.diseaseGastroenterologydigestive system diseasesInternal medicineGERDmedicineGastroesophageal RefluxHumansbusinessEsophagitisTherapy optimizationRandomized Controlled Trials as TopicDigestion
researchProduct